PCOS Diagnostic Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Test Type, By End User, By Region & Competition, 2020-2030F

Global PCOS Diagnostic Market was valued at USD 4.76 billion in 2024 and is expected to reach USD 6.91 billion by 2030 with a CAGR of 6.54% during the forecast period. The global PCOS diagnostic market is gaining significant attention due to the increasing prevalence of polycystic ovary syndrome (PCOS) among women of reproductive age. PCOS is a complex endocrine disorder that affects hormonal levels, metabolism, and overall reproductive health, often leading to complications such as infertility, obesity, and diabetes.

A 2024 study published by ScienceDirect reveals that North America spends nearly USD 4 billion on polycystic ovary syndrome (PCOS) and related conditions. Menstrual irregularities were observed in 22.8% of patients. The Alberta Women's Health Foundation's February 2023 report estimates that around 1.4 million women in Canada may have PCOS. Companies are investing in research to develop new treatment options and address the rising prevalence of PCOS. The growing awareness around early diagnosis and treatment of PCOS has led to a higher demand for diagnostic services and tools. Diagnostic methods for PCOS typically involve a combination of physical examination, medical history analysis, hormonal blood tests, and imaging techniques like pelvic ultrasound.

As healthcare systems advance and access to diagnostic technologies improves, more women are seeking early diagnosis and intervention. Healthcare professionals are becoming more adept at identifying the broad spectrum of PCOS symptoms, which can vary widely from patient to patient. For instance, according to the World Health Organization (WHO) report published in June 2023, polycystic ovary syndrome (PCOS) affects 8-13% of women of reproductive age, with approximately 70% of those affected remaining undiagnosed worldwide. This highlights the need for improved awareness and diagnostic efforts.

Key Market Drivers

Increasing Prevalence of PCOS

The increasing prevalence of polycystic ovary syndrome (PCOS) is one of the primary drivers fueling the growth of the global PCOS diagnostic market. For instance, the World Health Organization (WHO) notes that women with a family history of type 2 diabetes are at higher risk of developing polycystic ovary syndrome (PCOS). Also,the Centers for Disease Control and Prevention (CDC) states that PCOS sufferers often experience insulin resistance, which can lead to type 2 diabetes. The rising prevalence of these chronic conditions is expected to drive growth in the treatment market.

Also, Obesity is another factor contributing to polycystic ovary syndrome (PCOS). The World Health Organization (WHO) reported that 2.5 billion adults were overweight in 2022, with 44% being women. Those affected by obesity are more likely to develop PCOS, as weight gain exacerbates the condition, according to the endocrine center. The growing prevalence of obesity and PCOS cases is driving market growth. As a hormonal disorder affecting a significant portion of women in their reproductive years, PCOS is now more frequently recognized as a major public health concern. Contributing factors such as sedentary lifestyles, poor dietary habits, obesity, and genetic predisposition have led to a marked rise in PCOS cases worldwide. This surge in prevalence directly translates into a higher demand for timely and accurate diagnostic tools and services, propelling the market forward.

PCOS often presents with a range of symptoms-including irregular menstrual cycles, excessive hair growth, acne, and infertility-which vary widely among individuals. This variation complicates diagnosis and has historically led to underdiagnosis or misdiagnosis. However, with more women experiencing symptoms and seeking medical attention, healthcare providers are increasingly emphasizing early and comprehensive diagnostic evaluations. This shift is expanding the market for diagnostic tests such as hormonal assays, glucose tolerance tests, and pelvic ultrasounds.

The growing recognition of the long-term health risks associated with untreated PCOS-including type 2 diabetes, cardiovascular disease, and endometrial cancer-is pushing both patients and providers to prioritize early detection. As awareness spreads, more women are undergoing screening, and more healthcare systems are incorporating PCOS assessments into routine care for at-risk individuals.

The global rise in PCOS cases, coupled with growing awareness and the need for early intervention, is thus creating a sustained demand for diagnostic solutions. This trend is expected to continue, particularly as developing nations improve access to women's health services. As a result, the PCOS diagnostic market is poised for steady expansion, with the increasing disease burden serving as a key catalyst for its growth.

Key Market Challenges

Underdiagnosis and Misdiagnosis

Underdiagnosis and misdiagnosis of polycystic ovary syndrome (PCOS) represent significant challenges in the global PCOS diagnostic market, directly influencing its growth. PCOS is a complex condition with a wide array of symptoms that vary greatly between individuals, making it difficult to identify, especially in the early stages. Symptoms such as irregular menstrual cycles, acne, and excessive hair growth are often misunderstood or attributed to other, more common conditions. As a result, many women go undiagnosed for years, which not only delays proper treatment but also exacerbates the risk of long-term health complications, such as infertility, type 2 diabetes, and cardiovascular diseases.

This underdiagnosis is a key barrier to market growth, as a significant portion of the population may not seek or receive the necessary diagnostic tests. Misdiagnosis further complicates the issue. The overlapping symptoms of PCOS with other disorders, like thyroid dysfunction or stress-related conditions, can lead to incorrect treatments, which ultimately hinder proper disease management. Without a timely and accurate diagnosis, patients may not benefit from early interventions, leading to the persistence of symptoms and increased healthcare costs in the long run.

As awareness of PCOS increases, however, more women are seeking proper diagnosis, prompting growth in the diagnostic market. For this growth to be sustained, it is essential that healthcare professionals are better equipped to recognize the signs of PCOS and that women have access to reliable and accurate diagnostic tests. Addressing underdiagnosis and misdiagnosis will lead to more women seeking early diagnosis, thereby driving demand for PCOS diagnostic tools and services, ultimately expanding the market.

Key Market Trends

Focus on Early Detection and Intervention

The increasing focus on early detection and intervention is a key trend driving the growth of the global PCOS diagnostic market. Early diagnosis of polycystic ovary syndrome (PCOS) is crucial for managing symptoms effectively and preventing the long-term health complications often associated with the condition, such as infertility, diabetes, and cardiovascular diseases. As awareness of PCOS has risen, healthcare providers and patients alike are prioritizing early screening and diagnosis, which is significantly expanding the demand for diagnostic tools.

Timely intervention is essential for addressing the hormonal imbalances and metabolic issues common in PCOS, and this trend has spurred the development of more advanced diagnostic tests. These tests, which may include hormonal assays, metabolic screening, and imaging technologies like ultrasounds, are increasingly being utilized to detect the condition before it leads to more severe health issues. Early detection enables healthcare providers to recommend lifestyle changes, medications, or fertility treatments in a timely manner, improving the overall quality of life for patients. The rise in preventive healthcare and patient empowerment is contributing to this trend. With more women seeking proactive management of their health, there is a growing demand for diagnostic solutions that allow for quicker and more accurate assessments. As healthcare systems integrate early PCOS screening into routine checkups, especially for women at risk, the market for PCOS diagnostics continues to expand. Ultimately, the focus on early detection and intervention not only leads to better patient outcomes but also plays a significant role in driving the growth of the global PCOS diagnostic market.

Key Maaket Players

• Siemens Healthineers AG
• GE Healthcare
• Mindray Medical International Limited
• Esaote S.p.A
• Telemed Medical Systems
• Shantou Institute of Ultrasonic Instruments Co., Ltd. (SIUI)
• BK Medical
• Alpinion Medical Systems
• Mindray ZONARE Medical Systems
• Xianfeng Ultrasound Medical

Report Scope:

In this report, the Global PCOS Diagnostic Market has been segmented into the following categories, in addition to the industry trends which have also been detailed below:

• PCOS Diagnostic Market, By Test Type:
• Pelvic Exam
• Blood Test
• Transvaginal Ultrasound
• PCOS Diagnostic Market, By End User:
• Hospitals & Clinics
• Fertility Clinics
• Others
• PCOS Diagnostic Market, By Region:
• North America
  • United States
  • Canada
  • Mexico
• Europe
  • France
  • United Kingdom
  • Italy
  • Germany
  • Spain
• Asia-Pacific
  • China
  • India
  • Japan
  • Australia
  • South Korea
• South America
  • Brazil
  • Argentina
  • Colombia
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE

Competitive Landscape

Company Profiles: Detailed analysis of the major companies present in the Global PCOS Diagnostic Market.

Available Customizations:

Global PCOS Diagnostic Market report with the given market data, TechSci Research, offers customizations according to a company's specific needs. The following customization options are available for the report:

Company Information

• Detailed analysis and profiling of additional market players (up to five).